Pseudomonas aeruginosa infection in cystic fibrosis lung disease and new perspectives of treatment: a review
- 26 April 2013
- journal article
- review article
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 32 (10) , 1231-1252
Abstract
Cystic fibrosis (CF) is a complex inherited disease which affects many organs, including the pancreas and liver, gastrointestinal tract and reproductive system, sweat glands and, particularly, the respiratory system. Pseudomonas aeruginosa is the main cause of chronic airway infection. In order to reduce morbidity and mortality due to lung infection by P. aeruginosa, aerosol antibiotics have been used to achieve high local concentrations in the airways and to reduce systemic toxicity. In the course of this review, the current treatments to control CF lung infections by P. aeruginosa are presented. Some innovative aerosol formulations such as liposomes and microspheres are herein reviewed, which may improve the efficiency of anti-pseudomonal agents, and ensure patients’ compliance to treatments, by reducing dosing frequency and/or drug dose, while maintaining therapeutic efficacy, preventing the occurrence of bacterial resistance and/or reducing adverse effects due to their controlled-release properties.Keywords
This publication has 147 references indexed in Scilit:
- PCR and the detection of Pseudomonas aeruginosa in respiratory samples of CF patients. A literature reviewJournal of Cystic Fibrosis, 2011
- Application of quantitative PCR to the diagnosis and monitoring of Pseudomonas aeruginosa colonization in 5–18-year-old cystic fibrosis patientsJournal of Medical Microbiology, 2011
- Development of the First Inhaled Antibiotic for the Treatment of Cystic FibrosisScience Translational Medicine, 2010
- Early anti-pseudomonal acquisition in young patients with cystic fibrosis: Rationale and design of the EPIC clinical trial and observational study,Contemporary Clinical Trials, 2009
- The penetration of fresh undiluted sputum expectorated by cystic fibrosis patients by non-adhesive polymer nanoparticlesBiomaterials, 2009
- Mathematical modeling of molecular diffusion through mucusAdvanced Drug Delivery Reviews, 2009
- Interpretation of Antibiotic Concentration Ratios Measured in Epithelial Lining FluidAntimicrobial Agents and Chemotherapy, 2008
- A double-blind randomized placebo-controlled phase III study of a Pseudomonas aeruginosa flagella vaccine in cystic fibrosis patientsProceedings of the National Academy of Sciences, 2007
- Rapid transport of large polymeric nanoparticles in fresh undiluted human mucusProceedings of the National Academy of Sciences, 2007
- Mechanisms of resistance to β-lactam antibiotics amongst Pseudomonas aeruginosa isolates collected in the UK in 1993Journal of Medical Microbiology, 1995